Natus Medical Incorporated (NASDAQ:BABY) Director William M. Moore sold 8,000 shares of the business’s stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $35.91, for a total value of $287,280.00. Following the sale, the director now owns 30,410 shares of the company’s stock, valued at approximately $1,092,023.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Natus Medical traded down $0.05, reaching $35.50, on Friday, according to MarketBeat Ratings. The company had a trading volume of 120,609 shares, compared to its average volume of 295,633. The company has a market capitalization of $1.18 billion, a PE ratio of 24.48 and a beta of 0.49. The company has a current ratio of 3.06, a quick ratio of 2.28 and a debt-to-equity ratio of 0.31. Natus Medical Incorporated has a 52 week low of $28.00 and a 52 week high of $43.60.
Natus Medical (NASDAQ:BABY) last released its quarterly earnings data on Wednesday, April 25th. The medical equipment provider reported $0.24 EPS for the quarter, meeting analysts’ consensus estimates of $0.24. The business had revenue of $128.60 million during the quarter, compared to the consensus estimate of $125.91 million. Natus Medical had a positive return on equity of 10.96% and a negative net margin of 4.71%. The firm’s revenue was up 3.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.30 earnings per share. sell-side analysts predict that Natus Medical Incorporated will post 1.62 earnings per share for the current fiscal year.
Natus Medical announced that its board has approved a share repurchase plan on Thursday, February 22nd that authorizes the company to repurchase $30.00 million in shares. This repurchase authorization authorizes the medical equipment provider to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new stake in Natus Medical in the first quarter valued at about $124,000. US Bancorp DE increased its holdings in Natus Medical by 81.2% in the first quarter. US Bancorp DE now owns 4,742 shares of the medical equipment provider’s stock valued at $159,000 after purchasing an additional 2,125 shares during the last quarter. Elkfork Partners LLC bought a new stake in Natus Medical in the fourth quarter valued at about $163,000. Profund Advisors LLC bought a new stake in Natus Medical in the first quarter valued at about $218,000. Finally, Greenwood Capital Associates LLC bought a new stake in Natus Medical in the fourth quarter valued at about $219,000. Institutional investors and hedge funds own 94.50% of the company’s stock.
A number of equities research analysts have recently weighed in on BABY shares. BidaskClub upgraded Natus Medical from a “hold” rating to a “buy” rating in a research report on Monday, May 14th. Zacks Investment Research upgraded Natus Medical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 10th. ValuEngine downgraded Natus Medical from a “hold” rating to a “sell” rating in a research report on Thursday, May 3rd. Finally, Roth Capital set a $39.00 target price on Natus Medical and gave the stock a “buy” rating in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. Natus Medical currently has an average rating of “Hold” and an average target price of $44.33.
About Natus Medical
Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.